Hyperoside protects cardiomyocytes against hypoxia‑induced injury via upregulation of microRNA‑138

He,Siyi; Yin,Xiaoqiang; Wu,Fan; Zeng,Shaojie; Gao,Feng; Xin,Mei; Wang,Jian; Chen,Jie; Zhang,Le; Zhang,Jinbao

doi:10.3892/mmr.2021.11925

Hyperoside protects cardiomyocytes against hypoxia‑induced injury via upregulation of microRNA‑138

Authors:
- Siyi He
- Xiaoqiang Yin
- Fan Wu
- Shaojie Zeng
- Feng Gao
- Mei Xin
- Jian Wang
- Jie Chen
- Le Zhang
- Jinbao Zhang
View Affiliations

Affiliations: Department of Cardiovascular Surgery, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China, Medical Team, Unit 95437, People's Liberation Army, Nanchong, Sichuan 637100, P.R. China, National Drug Clinical Trial Institution, Second Affiliated Hospital, Army Medical University, Chongqing 400037, P.R. China
Published online on: February 19, 2021 https://doi.org/10.3892/mmr.2021.11925
Article Number: 286
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Following hypoxia, cardiomyocytes are susceptible to damage, against which microRNA (miR)‑138 may act protectively. Hyperoside (Hyp) is a Chinese herbal medicine with multiple biological functions that serve an important role in cardiovascular disease. The aim of the present study was to investigate the role of Hyp in hypoxic cardiomyocytes and its effect on miR‑138. A hypoxia model was established in both H9C2 cells and C57BL/6 mice, which were stimulated by Hyp. The expression levels of miR‑138 were increased in the hypoxic myocardium in the presence of Hyp at concentrations of >50 µmol/l in vivo and >50 mg/kg in vitro. Using Cell Counting Kit‑8 and 5‑ethynyl‑2'‑deoxyuridine assays, it was observed that Hyp improved hypoxia‑induced impairment of cell proliferation. Cell apoptosis was evaluated by flow cytometry and a TUNEL assay. The number of apoptotic cells in the Hyp group was lower than that in the control group. As markers of myocardial injury, the levels of lactate dehydrogenase, creatine kinase‑myocardial band isoenzyme and malondialdehyde were decreased in the Hyp group compared with the control group, whereas the levels of superoxide dismutase were increased. A marked decrease in the levels of cleaved caspase‑3 and cleaved poly(ADP) ribose polymerase and a marked increase in expression levels of Bcl‑2 were observed in the presence of Hyp. However, miR‑138 inhibition by antagomir attenuated the protective effects of Hyp. Furthermore, Hyp treatment was associated with marked downregulation of mixed lineage kinase 3 and lipocalin‑2, but not pyruvate dehydrogenase kinase 1, in hypoxic H9C2 cells. These findings demonstrated that Hyp may be beneficial for myocardial cell survival and may alleviate hypoxic injury via upregulation of miR‑138, thereby representing a promising potential strategy for clinical cardioprotection.

View Figures

View References

1	Azzouzi HE, Leptidis S, Doevendans PA and De Windt LJ: HypoxamiRs: Regulators of cardiac hypoxia and energy metabolism. Trends Endocrinol Metab. 26:502–508. 2015. View Article : Google Scholar : PubMed/NCBI
2	Qiu Q, Shen T, Wang Q, Yu X, Jia N and He Q: Cardiac shock wave therapy protects cardiomyocytes from hypoxia-induced injury by modulating miR-210. Mol Med Rep. 21:631–640. 2020.PubMed/NCBI
3	Zhang P: Advantages, disadvantages, and trend of integrative medicine in the treatment of heart failure. Cell Biochem Biophys. 72:363–366. 2015. View Article : Google Scholar : PubMed/NCBI
4	Lin F, Chen HW, Zhao GA, Li Y, He XH, Liang WQ, Shi ZL, Sun SY, Tian PP, Huang MY and Liu C: Advances in research on the circRNA-miRNA-mRNA network in coronary heart disease treated with traditional chinese medicine. Evid Based Complement Alternat Med. 2020:80486912020. View Article : Google Scholar : PubMed/NCBI
5	Zhang L, Dai Q, Hu L, Yu H, Qiu J, Zhou J, Long M, Zhou S and Zhang K: Hyperoside alleviates high glucose-induced proliferation of mesangial cells through the inhibition of the ERK/CREB/miRNA-34a signaling pathway. Int J Endocrinol. 2020:13619242020. View Article : Google Scholar : PubMed/NCBI
6	Li ZL, Hu J, Li YL, Xue F, Zhang L, Xie JQ, Liu ZH, Li H, Yi DH, Liu JC and Wang SW: The effect of hyperoside on the functional recovery of the ischemic/reperfused isolated rat heart: Potential involvement of the extracellular signal-regulated kinase 1/2 signaling pathway. Free Radic Biol Med. 57:132–140. 2013. View Article : Google Scholar : PubMed/NCBI
7	Hou JY, Liu Y, Liu L and Li XM: Protective effect of hyperoside on cardiac ischemia reperfusion injury through inhibition of ER stress and activation of Nrf2 signaling. Asian Pac J Trop Med. 9:76–80. 2016. View Article : Google Scholar : PubMed/NCBI
8	Xiao R, Xiang AL, Pang HB and Liu KQ: Hyperoside protects against hypoxia/reoxygenation induced injury in cardiomyocytes by suppressing the Bnip3 expression. Gene. 629:86–91. 2017. View Article : Google Scholar : PubMed/NCBI
9	Kalayinia S, Arjmand F, Maleki M, Malakootian M and Singh CP: MicroRNAs: Roles in cardiovascular development and disease. Cardiovasc Pathol. 50:1072962021. View Article : Google Scholar : PubMed/NCBI
10	He S, Liu P, Jian Z, Li J, Zhu Y, Feng Z and Xiao Y: miR-138 protects cardiomyocytes from hypoxia-induced apoptosis via MLK3/JNK/c-jun pathway. Biochem Biophys Res Commun. 441:763–769. 2013. View Article : Google Scholar : PubMed/NCBI
11	Xiong H, Luo T, He W, Xi D, Lu H, Li M, Liu J and Guo Z: Up-regulation of miR-138 inhibits hypoxia-induced cardiomyocyte apoptosis via down-regulating lipocalin-2 expression. Exp Biol Med (Maywood). 241:25–30. 2016. View Article : Google Scholar : PubMed/NCBI
12	Zhu H, Xue H, Jin QH, Guo J and Chen YD: miR-138 protects cardiac cells against hypoxia through modulation of glucose metabolism by targetting pyruvate dehydrogenase kinase 1. Biosci Rep. 37:BSR201702962017. View Article : Google Scholar : PubMed/NCBI
13	Council N: Guide for the Care and Use of Laboratory Animals: Eighth Edition. Publication. 327:963–965. 2011.
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Wu L, Li Q, Liu S, An X, Huang Z, Zhang B, Yuan Y and Xing C: Protective effect of hyperoside against renal ischemia-reperfusion injury via modulating mitochondrial fission, oxidative stress, and apoptosis. Free Radic Res. 53:727–736. 2019. View Article : Google Scholar : PubMed/NCBI
16	Shi Y, Qiu X, Dai M, Zhang X and Jin G: Hyperoside attenuates hepatic ischemia-reperfusion injury by suppressing oxidative stress and inhibiting apoptosis in rats. Transplant Proc. 51:2051–2059. 2019. View Article : Google Scholar : PubMed/NCBI
17	Wang X, Fan G, Wei F, Bu Y and Huang W: Hyperoside protects rat ovarian granulosa cells against hydrogen peroxide-induced injury by sonic hedgehog signaling pathway. Chem Biol Interact. 310:1087592019. View Article : Google Scholar : PubMed/NCBI
18	Kwon SH, Lee SR, Park YJ, Ra M, Lee Y, Pang C and Kim KH: Suppression of 6-hydroxydopamine-induced oxidative stress by hyperoside via activation of Nrf2/HO-1 signaling in dopaminergic neurons. Int J Mol Sci. 20:58322019. View Article : Google Scholar
19	Rodius S, de Klein N, Jeanty C, Sánchez-Iranzo H, Crespo I, Ibberson M, Xenarios I, Dittmar G, Mercader N, Niclou SP and Azuaje F: Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity. Sci Rep. 10:28962020. View Article : Google Scholar : PubMed/NCBI
20	Loor G and Schumacker PT: Role of hypoxia-inducible factor in cell survival during myocardial ischemia-reperfusion. Cell Death Differ. 15:686–690. 2008. View Article : Google Scholar : PubMed/NCBI
21	Li JP, Liao XH, Xiang Y, Yao A, Song RH, Zhang ZJ, Huang F, Dai ZT and Zhang TC: Hyperoside and let-7a-5p synergistically inhibits lung cancer cell proliferation via inducing G1/S phase arrest. Gene. 679:232–240. 2018. View Article : Google Scholar : PubMed/NCBI
22	Li W, Liu M, Xu YF, Feng Y, Che JP, Wang GC and Zheng JH: Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a. Oncol Rep. 31:117–124. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zhang L, He S, Yang F, Yu H, Xie W, Dai Q, Zhang D, Liu X, Zhou S and Zhang K: Hyperoside ameliorates glomerulosclerosis in diabetic nephropathy by downregulating miR-21. Can J Physiol Pharmacol. 94:1249–1256. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhang X, Qin Q, Dai H, Cai S, Zhou C and Guan J: Emodin protects H9c2 cells from hypoxia-induced injury by up-regulating miR-138 expression. Braz J Med Biol Res. 52:e79942019. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Li J, Zhang P, Jiang X, Pan Z, Zheng W and Lin H: lncRNA-LET relieves hypoxia-induced injury in H9c2 cells through regulation of miR-138. J Cell Biochem. 121:259–268. 2020. View Article : Google Scholar : PubMed/NCBI
26	Li JB, Wang HY, Yao Y, Sun QF, Liu ZH, Liu SQ, Zhuang JL, Wang YP and Liu HY: Overexpression of microRNA-138 alleviates human coronary artery endothelial cell injury and inflammatory response by inhibiting the PI3K/Akt/eNOS pathway. J Cell Mol Med. 21:1482–1491. 2017. View Article : Google Scholar : PubMed/NCBI
27	Shi S, Zhang S, Zhang H, Jin Q and Wu D: Silencing circANKRD36 protects H9c2 cells against lipopolysaccharide-induced injury via up-regulating miR-138. Exp Mol Pathol. 111:1043002019. View Article : Google Scholar : PubMed/NCBI
28	Liu Y, Zou J, Liu X and Zhang Q: MicroRNA-138 attenuates myocardial ischemia reperfusion injury through inhibiting mitochondria-mediated apoptosis by targeting HIF1-α. Exp Ther Med. 18:3325–3332. 2019.PubMed/NCBI
29	Treiber T, Treiber N and Meister G: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 20:5–20. 2019. View Article : Google Scholar : PubMed/NCBI
30	He S, Liu S, Wu X, Xin M, Ding S, Xin D, Ouyang H and Zhang J: Protective role of downregulated MLK3 in myocardial adaptation to chronic hypoxia. J Physiol Biochem. 73:371–380. 2016. View Article : Google Scholar : PubMed/NCBI
31	Moschen AR, Adolph TE, Gerner RR, Wieser V and Tilg H: Lipocalin-2: A master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab. 28:388–397. 2017. View Article : Google Scholar : PubMed/NCBI
32	Xu G, Ahn J, Chang S, Eguchi M, Ogier A, Han S, Park Y, Shim C, Jang Y, Yang B, et al: Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J Biol Chem. 287:4808–4817. 2012. View Article : Google Scholar : PubMed/NCBI
33	Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Frøland SS, Husberg C, Christensen G, et al: Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J. 30:1229–1236. 2009. View Article : Google Scholar : PubMed/NCBI
34	Calleja V, Laguerre M, de Las Heras-Martinez G, Parker PJ, Requejo-Isidro J and Larijani B: Acute regulation of PDK1 by a complex interplay of molecular switches. Biochem Soc Trans. 42:1435–1440. 2014. View Article : Google Scholar : PubMed/NCBI
35	Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, van der Burg SH, Verdegaal EM, Cascante M, Shlomi T, et al: A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 498:109–112. 2013. View Article : Google Scholar : PubMed/NCBI